See the latest news and media coverage for Lakefront. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company advancing immunology and inflammation medicines
lakefrontbio.comLast updated
In short: Lakefront sold its preclinical CAR-T portfolio and advanced gamgertamig while completing its share repurchase program.
Lakefront sold its early-stage cell therapy pipeline to Armed Cell Therapeutics for an upfront payment of €8 million and potential milestone payments up to $230 million, completing a strategic wind-down.
The firm completed its Ouro acquisition with Gilead, maintains roughly €2 billion in cash, reports a €16.6 million net profit, and initiates a €50 million share buyback program.
The program runs through December 2026 and is executed with Morgan Stanley.
Gilead and Lakefront collaborate on gamgertamig, a T-cell engager for autoimmune diseases.
Lakefront Biotherapeutics completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics BV, substantially completing its wind down of its legacy cell...
Lakefront Biotherapeutics, formerly known as Galapagos, is making a fresh start with the acquisition of Ouro Medicines.
Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engagerForecast at least €1.6B...
Galapagos NV, soon to be known as Lakefront Biotherapeutics, reported a dramatic decline in revenue of 91.3% in Q1... Introduction & Market ContextGalapagos NV (NASDAQ:GLPG) presented on...
Track Lakefront and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Lakefront and other trending companies.
